Výsledky vyhledávání - "Chloe Pantano"

Abstract 2924: Aberrant SWI/SNF complexes lacking SMARCA2 or SMARCA4 differentially affect cell state and response to a novel SMARCA2/4 inhibitor

Autor: Selene Howe, Daniel T. Dransfield, Lampe John W, Kim Stickland, Neil A. Farrow, Dorothy Brach, Kenneth W. Duncan, Suzanne L. Jacques, Allison Drew, Lindsey W. Eichinger, Vinny Motwani, Alejandra Raimondi, Cuyue Tang, Chloe Pantano

Publikováno v: Cancer Research. 80:2924-2924

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2) is an ATP-dependent DNA helicase and a catalytic component of the SWI/SNF complex. SWI/SNF-mediated nucleosome remodeling is a critical regulato

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::377456aad17e1af658735ede3fa64551
https://doi.org/10.1158/1538-7445.am2020-2924

Zobrazit plný text záznamu

Abstract 1768: Identification of a potent, orally-available SMARCA2/4 inhibitor with in vitro and in vivo activity in preclinical models of SMARCA4-mutant NSCLC

Autor: Allison E. Drew, Suzanne L. Jacques, Lindsey W. Eichinger, Chloe Pantano, Vinny Motwani, Cuyue Tang, Neil Farrow, Dorothy Brach, Selene Howe, Alejandra Raimondi, Daniel T. Dransfield, Kenneth W. Duncan, Kim Stickland, Liyue Huang, John Lampe

Publikováno v: Cancer Research. 80:1768-1768

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f7a5a209580131346f09a034211723df
https://doi.org/10.1158/1538-7445.am2020-1768

Zobrazit plný text záznamu

Abstract B011: Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion

Autor: Daniel T. Dransfield, Dorothy Brach, Jeffrey A. Keats, Alejandra Raimondi, Chloe Pantano, Vinny Motwani, Vania Estanek

Publikováno v: Molecular Cancer Therapeutics. 18:B011-B011

Prostate cancer (PCa) is the second leading cause of cancer death among men in the United States. Current available treatments include chemical castration and therapies targeting androgen receptor (AR) signaling pathways. Although initial responses a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d48ab9476ce5465205a82275c84d4040
https://doi.org/10.1158/1535-7163.targ-19-b011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání